Alvotech and Stada agree on strategic biosimilar partnership
[caption id="attachment_9277" align="aligncenter" width="747"]
Press Release[/caption]
Press Release[/caption]
- ALVOTECH and STADA enter into a strategic collaboration for seven biosimilar candidates in Europe
- STADA will exclusively commercialize the products in all key European markets as well as selected markets outside of Europe
- STADA CEO Peter Goldschmidt: ?The agreement with Alvotech is one of the largest commercial biosimilar cooperation?s to date, accelerating improved patient access to high quality biosimilars.?
?This is an important moment for biosimilars. This partnership has the resources and vision to accelerate the introduction and adoption of new biosimilars for patients in Europe who will get better access to high-quality products. It?s also another important milestone for Alvotech and crowns an exceptional year where we have continued to extend our network of partners around the globe.?
?We?re delighted to establish this latest partnership with STADA, who is an ideal commercial partner in Europe and shares the same purpose of improving the quality of life of patients around the world,?
?The collaboration with Alvotech, with its highly experienced and fully committed team, is a great opportunity to accelerate the expansion of our biosimilar portfolio and to strengthen our market position in this segment. We are looking forward to provide patients with state-of-the-art medicine and cost-effective alternatives to biologicals.?
1?/?1
About STADA Arzneimittel AG
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a two-pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2018, STADA achieved adjusted Group sales of EUR 2,330.8 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 503.5 million. As of December 31, 2018, STADA employed 10,416 people worldwide.
